Taking a step back from the conspiracy theories ..
Post# of 148168
If we were to apply Occam's Razor to this equation, we might conclude that the Type A Meeting questions that CytoDyn presented were complicated enough to cause the FDA to realize that a verbal call (not WRO) was going to be necessary.
Furthermore, the questions CytoDyn presented might have caused the FDA to realize that they needed to offer CytoDyn the option of a Multidisciplinary Review as a hand-holding solution to prevent more issues with the revised BLA filing.
I accept that the above is possible, and that the 30+ day penalty for the Multidisciplinary Review is simply the cost of having the FDA "bless" the submission before it is re-filed -- and not a sinister move on the part of the FDA.